Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496740 | 0.98 | GLS (0.53) | GLSCASP3CA9CA1CA2 | |
| SCHEMBL6284185 | 0.96 | GLS (0.52) | GLSCASP3CA9CA1CA2 | |
| SCHEMBL918303 | 0.87 | TDP1 (0.51) | SMN1; SMN2RAB9ATDP1L3MBTL1MAPT | |
| SCHEMBL5372797 | 0.86 | CA9 (0.42) | GLSCASP3CA9CA1CA2 | |
| SCHEMBL2284215 | 0.86 | TDP1 (0.50) | SMN1; SMN2RAB9ATDP1L3MBTL1MAPT | |
| SCHEMBL3670226 | 0.86 | TDP1 (0.50) | SMN1; SMN2RAB9ATDP1L3MBTL1MAPT | |
| SCHEMBL2169798 | 0.86 | TDP1 (0.54) | TDP1L3MBTL1HDAC8HDAC3HDAC4 | |
| SCHEMBL17122199 | 0.84 | TDP1 (0.57) | SMN1; SMN2TDP1L3MBTL1HDAC8HPGD | |
| SCHEMBL5794366 | 0.84 | TDP1 (0.57) | SMN1; SMN2TDP1L3MBTL1HDAC8HPGD | |
| SCHEMBL7400320 | 0.84 | TDP1 (0.53) | TDP1L3MBTL1HDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887903-B1 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. (IT) | 2005-05-03 | — | — | US | disclosed |
| US-6881755-B2 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | Dompé S.p.A. (IT) | 2005-04-19 | — | — | US | disclosed |
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. | 2003-11-20 | — | — | US | disclosed |
| EP-1123276-B1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE SPA (IT) | 2003-01-08 | — | — | EP | disclosed |
| EP-1123276-A1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | Dompe' S.P.A. (IT) | 2001-08-16 | — | — | EP | disclosed |
| US-6172239-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 2001-01-09 | — | — | US | disclosed |
| WO-2000024710-A1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2000-05-04 | — | — | WO | disclosed |
| US-5965579-A | ANTAGONISTS OF THE NEUROTENSIN RECEPTORS; INCREASING AFFINITY FOR HUMAN NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5939449-A | NOVEL COMPOUNDS HAVING HIGH AFFINITY FOR THE NEUROTENSIN RECEPTORS | SANOFI (FR) | 1999-08-17 | — | — | US | disclosed |
| US-5936123-A | COMPOUNDS SUCH AS 3-ISOPROPYL-4-HYDRAZINOBENZOIC ACID AND ITS SALTS | SANOFI (FR) | 1999-08-10 | — | — | US | disclosed |
| US-5925661-A | NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 1999-07-20 | — | — | US | disclosed |
| US-5723483-A | NEUROTENSIN ANTAGONIST, HYPOTENSIVE AGENTS AND FOR NEUROPSYCHIATRIC DISORDERS | SANOFI (FR) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | ELANE, MPO, FPR1 | GLS 410/4885CASP3 85/4885CA9 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.